Prof Borje Andersson to Chair RAC Clinical Advisory Board
Prof Borje Andersson to Chair RAC Clinical Advisory Board
5 December 2019 – Race Oncology Limited (ASX: RAC) is honoured to advise that Professor Borje Andersson has agreed to chair Race Oncology’s Clinical Advisory Board (CAB). Prof Andersson is a world-recognised research leader in...
Race reveals new strategy for cancer drug Bisantrene
Race reveals new strategy for cancer drug Bisantrene
14 November 2019 – Race Oncology Limited (ASX: RAC) today revealed its new “5 Path” clinical strategy for its cancer drug, Bisantrene. The strategy defines five paths for the clinical development of Bisantrene that greatly...
Race appoints Dr Daniel Tillett Chief Scientific Officer
Race appoints Dr Daniel Tillett Chief Scientific Officer
Race Oncology is pleased to announce that Dr Daniel Tillett has been appointed Chief Scientific Officer (CSO) of RAC effective from 30 September 2019. Dr Tillett recently anchored a share placement in RAC and...
Dr Daniel Tillett joins Race Board
Dr Daniel Tillett joins Race Board
17 September 2019 – Race Oncology Limited (ASX: RAC) is pleased to announce that prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has today joined the Board of Directors of Race Oncology Ltd....
Prominent biotech investor leads investment in Race
Prominent biotech investor leads investment in Race
Race Oncology Limited is pleased to announce the successful completion of a $1.45 million placement, led by prominent biotechnology investor Dr Daniel Tillett. The placement comprised 21.9 million new ordinary shares at an issue...
Race announces additional US Patent for Zantrene
Race announces additional US Patent for Zantrene
Race Oncology has announced it has secured a new patent on its cancer drug, Zantrene®, from the United States Patent and Trademarks Office (USPTO). This is Race’s third patent granted on Zantrene in the...
Race’s Israel trial treats first patient with Bisantrene
Race’s Israel trial treats first patient with Bisantrene
Race Oncology is pleased to announce it has successfully completed treatment on its first patient at the Sheba Medical Center in Israel as part of its Bisantrene trial at the facility. The patient diagnosed...
Bisantrene investigator-initiated AML trial to start in Israel
Bisantrene investigator-initiated AML trial to start in Israel
Race Oncology has announced that it has signed an agreement to conduct a trial of Race’s cancer drug, Bisantrene, at the Sheba Medical Center in Israel. The trial has been approved by the Israeli...
Principal Investigator appointed for Bisantrene trial
Principal Investigator appointed for Bisantrene trial
Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal Investigator for the US registration trial for Bisantrene. Roland B. Walter, MD PhD MS, is a leading international...
Race appoints leading haematologist to support Bisantrene
Race appoints leading haematologist to support Bisantrene
Race Oncology is pleased to announce that it has executed a consulting agreement with Professor Borje Andersson from the M.D. Anderson Cancer Research Center in Houston, Texas. Under the initial 12-month agreement, Professor Andersson will...
